No Data
Stock News Premium = The Growth Market will be (Delisted) for stocks with a Market Cap of less than 10 billion yen.
＜Currently, 70% of the stocks are affected, and the impact extends to IPOs＞ The Tokyo Stock Exchange has tightened the listing maintenance standards for the Growth Market and plans to delist companies that have not reached a Market Cap of 10 billion yen after five years of listing starting in 2030. Although there is still time until the deadline, 70% of the 612 listed stocks have a Market Cap of less than 10 billion yen, and the Emerging Markets, including IPOs, will enter a period of significant transformation. It has been noted that companies showcase impressive growth rates during their IPOs but deteriorate post-listing.
Nano mRNA - The clinical trial country for the osteoarthritis drug "RUNX1 mRNA" has been changed to Australia to accelerate progress.
On the 19th, NANO MRNA <4571> announced that its subsidiary PrimRNA has been discussing with domestic regulatory authorities regarding the launch of a physician-led clinical trial for the mRNA-based treatment for osteoarthritis "RUNX1 mRNA." However, considering the development speed, the company has decided to change the trial conduct country from Japan to Australia and will carry it out as a corporate trial. This project was supported by the Japan Agency for Medical Research and Development (AMED) under the Medical Research and Development Innovation Infrastructure Creation Program in 2021.
Timy and other stocks that are interesting based on changes in Volume.
Stock closing price change Volume * <4316> Beamap 433801 445600 * <3930> Hatena 140215 7202300 * <1905> Tenox 116816 58900 * <2164> Regional Newspaper Company 388271 19100 * <7692> E-Infinity 115307 717800 * <9218> Mental Health T 788331 29700 * <4571> NANO MRNAs 159 15 1356500 * <219A> Heart S
Nano mRNA - a contract was signed for the transfer of the Shareholding antibodies and production strains, and a lump sum payment was received.
NANO MRNA <4571> announced on February 28 that it has signed a transfer agreement regarding the antibodies and their producing strains (hereinafter referred to as "the antibody") established through the research and development of ADCM (antibody-bound micelles) by its predecessor, NanoCarrier, with LinkMed, which is advancing research and development of radiopharmaceuticals using the radioactive isotope Copper-64 to aim for innovative 'visible' cancer treatment. The company received a one-time payment from LinkMed, and furthermore, this agreement allows for the sale of diagnostic drugs.
The physician-led phase 1 trial of Nano mRNA---3Q TUG1 ASO (glioblastoma) is proceeding smoothly.
On the 14th, NANO MRNA (4571) announced its consolidated financial results for the third quarter of the fiscal year ending March 2025 (April-December 2024). Revenue was 0.083 billion yen, a 20.3% decrease compared to the same period last year, operating loss was 0.485 billion yen (compared to a loss of 0.687 billion yen in the same period last year), recurring loss was 0.446 billion yen (compared to a loss of 0.663 billion yen in the same period last year), and net loss attributable to shareholders of the parent company was 0.595 billion yen (compared to a loss of 0.737 billion yen in the same period last year). Regarding the main research and development progress during the cumulative period of the third quarter, TUG1
Nano Mrna: Summary of Financial Results for the 3rd Quarter Ending March 31, 2025 [Japanese GAAP] (Consolidated)